
CAR-T Cell Therapy in China
Access NMPA-approved CAR-T therapy in China from ¥0.899M (~$135,000) per infusion, with record review, senior oncology interpreters and follow-up support.
NMPA-approved CD19, BCMA and CLDN18.2 products with bilingual medical support
Service Highlights
Six NMPA-approved CAR-T products, with list prices from ¥0.899M (~$135,000) per infusion
Access to satri-cel, the world's first CAR-T approved for a solid tumour (CLDN18.2 gastric cancer)
Product prices roughly 60–65% below US list prices of $373,000–$475,000
Free record review before you book flights or pay a deposit
Senior oncology-trained interpreter for consent, ward rounds and discharge planning
Hourly escort billing — you pay for hours used, never a bundled package markup
Continuity from leukapheresis through Day 30 and Day 90 follow-up
Introduction
CAR-T (chimeric antigen receptor T-cell) therapy reprograms a patient's own T cells so they can recognise and attack cancer cells. Blood is drawn through a process called leukapheresis, the T cells are genetically engineered in a laboratory, and the expanded product is infused back after a short course of lymphodepleting chemotherapy. It is a single-infusion treatment, but it is also one of the most intensive therapies in oncology: patients need close inpatient monitoring for cytokine release syndrome (CRS) and neurological toxicity (ICANS), and most spend several weeks within reach of the treating hospital.
What is approved in China
China's NMPA has approved six CAR-T products, five for blood cancers and — since June 2026 — one for a solid tumour:
- CD19 products for relapsed or refractory large B-cell lymphoma and B-cell acute lymphoblastic leukaemia
- BCMA products for relapsed or refractory multiple myeloma
- CLDN18.2 product (satri-cel) for Claudin18.2-positive, HER2-negative advanced gastric and gastro-oesophageal junction adenocarcinoma after at least two prior lines of therapy
That last approval matters: satri-cel is the first CAR-T therapy approved anywhere in the world for a solid tumour, and it was approved in China rather than in the US or EU.
Why patients look at China
List prices for approved products run from roughly ¥0.899 million to ¥1.299 million per infusion (about $135,000–$195,000 at ¥6.67 to the dollar). Equivalent US products list between $373,000 and $475,000 before hospitalisation, ICU care and supportive treatment. China also runs the largest number of registered CAR-T clinical trials in the world, which matters if no approved product matches your target or indication.
What CAR-T is not
It is not a first-line treatment, it is not suitable for every cancer type, and it is not a guaranteed cure. Most patients still relapse eventually, which is why eligibility screening and an honest conversation about expected benefit come before any travel planning.
Treatment Procedure
1. Record review (before travel). You send pathology reports, imaging, prior treatment lines, biomarker results and current blood work. A treating team confirms whether an approved product matches your indication, or whether a clinical trial is the better route.
2. Baseline workup. On arrival, the hospital repeats essential tests: blood counts, organ function, infection screening, cardiac assessment and — for satri-cel — CLDN18.2 immunohistochemistry if not already done.
3. Leukapheresis. T cells are collected in a single session of roughly 3–5 hours. A central line is usually placed beforehand.
4. Bridging therapy and manufacturing. If the disease is progressing quickly, the team may give bridging chemotherapy while the product is manufactured. Manufacturing typically takes 2–4 weeks; the schedule is product-specific.
5. Lymphodepletion and infusion. Three to five days of fludarabine and cyclophosphamide prepare the body for the cells. The infusion itself takes minutes; the monitoring that follows takes weeks.
6. Inpatient monitoring. Expect daily review for CRS and ICANS, with tocilizumab and steroids on standby and ICU access if needed. Most patients stay 2–3 weeks after infusion.
7. Discharge and follow-up. You remain within about an hour of the hospital for at least four weeks after infusion, then complete Day 30 and Day 90 assessments before flying home.
Cost Comparison
| Product (China) | Target | Main indication | China list price | US equivalent |
|---|---|---|---|---|
| Yikaida (axi-cel) | CD19 | r/r large B-cell lymphoma | ¥1.20M (~$180,000) | Yescarta, $373,000 |
| Carteyva (relma-cel) | CD19 | r/r large B-cell lymphoma | ¥1.299M (~$195,000) | Not marketed in the US |
| Yuanruida (inaticabtagene) | CD19 | r/r B-cell ALL | ¥0.999M (~$150,000) | Kymriah, $475,000 |
| Fucaso (equecabtagene) | BCMA | r/r multiple myeloma | ¥1.166M (~$175,000) | Abecma / Carvykti, $420,000–$465,000 |
| Saikaize (zevor-cel) | BCMA | r/r multiple myeloma | ¥1.15M (~$172,000) | Abecma / Carvykti, $420,000–$465,000 |
| Kailimei (satri-cel) | CLDN18.2 | CLDN18.2+ gastric / GEJ adenocarcinoma | No approved equivalent |
What the product price does not include:
| Cost item | Typical range in China | Paid to |
|---|---|---|
| CAR-T product | ¥0.899M–¥1.299M | Hospital / manufacturer |
| Workup, apheresis, lymphodepletion | ¥30,000–¥80,000 | Hospital |
| Inpatient stay and ICU if needed | ¥100,000–¥300,000 | Hospital |
| Bridging therapy (if required) | Case-dependent | Hospital |
| Accommodation near hospital, 4+ weeks | ¥15,000–¥40,000 | Provider |
List prices are published figures and vary by product, hospital and city. Hospitals quote the final invoice. US figures are published list prices before hospitalisation and supportive care, where total episode costs commonly exceed $500,000.
Service Pricing
Basic
Standard escort, translation and appointment coordination for consultations, tests and admission days
ⓘ Hover for details
What's Included
- ✓Hospital appointment and admission coordination
- ✓Bilingual escort for outpatient visits and tests
- ✓Real-time interpretation during consultations
- ✓Help with registration, payment and pharmacy queues
- ✓Written summary of each appointment
Not Included
- ✕CAR-T product and all hospital charges (paid directly to the hospital)
- ✕Flights, visa fees and travel insurance
- ✕Accommodation and meals during your stay
- ✕Caregiver costs and personal expenses
- ✕Bridging therapy, ICU care and any complication-related treatment
Premium
Senior medical interpreter with oncology background for consent, ward rounds and discharge planning
ⓘ Hover for details
What's Included
- ✓Everything in the Basic plan
- ✓Senior interpreter with oncology and CAR-T experience
- ✓Pre-travel record review and eligibility briefing
- ✓Interpretation during informed consent and ward rounds
- ✓Translated discharge summary and follow-up checklist
- ✓Coordination with your oncologist at home
Not Included
- ✕CAR-T product and all hospital charges (paid directly to the hospital)
- ✕Flights, visa fees and travel insurance
- ✕Accommodation and meals during your stay
- ✕Caregiver costs and personal expenses
- ✕Bridging therapy, ICU care and any complication-related treatment
Your CAR-T Journey in China
1. Free record review
Send pathology, imaging, prior treatment lines and recent blood work. We confirm whether an approved product or a trial fits your case before you commit to travel.
2. Hospital selection and appointment
We shortlist centres with an active CAR-T programme and ICU support, then secure a consultation slot that matches your manufacturing timeline.
3. Arrival and baseline workup
Repeat blood work, organ function, infection screening, cardiac assessment and any missing biomarker testing.
4. Leukapheresis
T-cell collection through a central line, usually a single 3–5 hour session, with monitoring afterwards.
5. Bridging therapy and manufacturing
Optional bridging chemotherapy if the disease is progressing, while the product is manufactured and released.
6. Lymphodepletion and infusion
Three to five days of conditioning chemotherapy, then the CAR-T infusion with daily monitoring from that point on.
7. Inpatient monitoring
Daily review for CRS and ICANS, with tocilizumab, steroids and ICU access available. Discharge when stable.
8. Day 30 and Day 90 follow-up
Outpatient assessments in China or locally, with translated results shared back to both teams.
Aftercare & Recovery
The first three months after infusion need discipline rather than heroism. Blood counts often stay low for weeks, so infection precautions, prophylactic antivirals and antibiotics, and sometimes immunoglobulin replacement continue after discharge. Live vaccines are avoided for at least a year, and many centres advise against driving for several weeks, especially if neurological symptoms appeared.
Follow-up is shared: the Chinese team wants Day 30 and Day 90 imaging and blood work, and your local oncologist can order these at home so you do not need to stay in China for three months. We help translate the discharge summary, the CRS/ICANS medication plan and the follow-up checklist into a document your local team can act on, and we stay reachable for questions between appointments. Fever, confusion or a new neurological symptom after discharge is a same-day hospital matter — not something to wait on.
Eligibility & Requirements
Age
Typically 18+ years; the approved products are adult indications, and paediatric cases are handled through trials
Diagnosis
Relapsed or refractory disease after the number of prior lines specified in the product label — usually two or more for CD19 and CLDN18.2 products, three or more for BCMA products
Performance status
ECOG 0–1 in most centres; rapidly progressing disease may need bridging therapy first
Organ function
Adequate cardiac, liver, kidney and lung function, with no active uncontrolled infection
Biomarker (satri-cel)
CLDN18.2-positive by immunohistochemistry and HER2-negative, confirmed on recent tissue
Support requirements
An adult caregiver and a place to stay within about one hour of the hospital for at least four weeks after infusion
Frequently Asked Questions
References
- 🔗Zheng SL, Zhang XQ. A new outcomes-based payment plan from a Chinese company to improve patient affordability of CAR-T product. Int J Health Policy Manag. 2024;13:8543
- 🔗CARsgen. CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors. 22 June 2026
- 🔗National Medical Products Administration (NMPA) — drug approval database
Author
This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for personal medical decisions.
Ready to Start Your Medical Journey?
Contact us today for a free consultation and personalized treatment plan
Free Consultation